Target ACE2, Spike protein
| Zeile 1: | Zeile 1: | ||
ACE2; any specific functions of spike protein; | ACE2; any specific functions of spike protein; | ||
| + | see also '''[[RSP - On RAS drugs]]''' | ||
Version vom 22. Juni 2020, 06:20 Uhr
ACE2; any specific functions of spike protein; see also RSP - On RAS drugs
regulation of ace2
32291076 ä. EZH2-mediated H3K27me3 inhibits ACE2 expression
32133153 2020. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations
32372801 2020. (ACE2) Does a cell protein explain covid-19 severity?
32302706 2020. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor
ace2 species specificity clade specificity
32092392 2020. Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV
32199943 ä. Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2
32100877 ä. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS?CoV?2
32249956 ä. Structural variations in human ACE2 may influence its binding with SARS?CoV?2 spike protein
32374452 2020. SARS-CoV-2: Structural diversity, phylogeny, and potential animal host identification of spike glycoprotein
32239522 ä. SARS?CoV?2 spike protein favors ACE2 from Bovidae and Cricetidae
any receptors in target tissues
32199615 ä. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses
ACE2 expression in target tissues
32279908 ä. Is the ACE2 Overexpression a Risk Factor for COVID-19 Infection?
32251718 2020. ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia
32227090 ä. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2
32364961 2020. Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?
Structure spike/ace2
32057769 2020. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade
32155444 ä. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
32178593 2020. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26
32320687 ä. Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop
32009228 2020. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission
32075877 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
32081428 2020. Structure analysis of the receptor binding of 2019-nCoV
32142651 2020. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
32203189 ä. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
32275855 ä. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
32201080 ä. Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection
32210742 2020. Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis
32327200 ä. Covid-19 and the angiotensin-converting enzyme (ACE2): Areas for research
| 32274964 2020. A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin |
31996437 2020. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus
| 32362314 ä. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells |
32221306 2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
| 32150576 2020. Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry |
32245784 2020. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
| 32366695 ä. Site-specific glycan analysis of the SARS-CoV-2 spike |
32132184 2020. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
32198713 ä. A Unique Protease Cleavage Site Predicted in the Spike Protein of the Novel Pneumonia Coronavirus (2019-nCoV) Potentially Related to Viral Transmissibility
32365751 2020. The SARS-CoV-2 Exerts a Distinctive Strategy for Interacting with the ACE2 Human Receptor
32378705 2020. A virus that has gone viral: amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding, and thus, infectivity
32132669 2020. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV
32338224 2020. Focus on Receptors for Coronaviruses with Special Reference to Angiotensin-converting Enzyme 2 as a Potential Drug Target - A Perspective
32363391 ä. Deducing the N- and O- glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2
| 32374903 2020. SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate |
32376714 2020. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein
32225176 2020. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
32225175 2020. Structural basis of receptor recognition by SARS-CoV-2
32329276 2020. Spike protein in the detection and treatment of novel coronavirus
C7190498 ä. The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650
Drug design
| C7151553 2020. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles? heel conserved region to minimize probability of escape mutations and drug resistance |
32286790 ä. Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2
32333836 ä. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
32125455 ä. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target
32231345 2020. Inhibition of SARS-CoV-2 (previously 2019-nCoV)infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
32354636 ä. Blockade of SARS-CoV-2 infection by recombinant soluble ACE2
32332922 ä. SARS-CoV-2 infection of kidney organoids prevented with soluble human ACE2
32294562 ä. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease
32359080 2020. Off-target ACE2 ligands: Possible therapeutic option for CoVid-19?
32167153 2020. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?
32373991 2020. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking
32232976 2020. CD-sACE2 inclusion compounds: An effective treatment for coronavirus disease 2019 (COVID-19)
32362217 2020. In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria
32345124 2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets
32379346 2020. ACE2 Activators for the Treatment of Covid 19 Patients
32332765 2020. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
32376627 2020. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity
32380200 ä. In Silico Design of Antiviral Peptides Targeting the Spike Protein of SARS-CoV-2
| C7197610 ä. Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy |
| 32231345 ä. Inhibition of SARS-CoV-2 infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion |
32336762 2012. Design of Angiotensin?converting Enzyme 2 (ACE2) Inhibitors by Virtual Lead Optimization and Screening
32380200 2020. In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2
32065055 2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
32285293 ä. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV
32313207 ä. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor
32346094 ä. COVID-19 vaccine design: the Janus face of immune enhancement
32369402 2020. ANNALS EXPRESS: Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: a closer look at angiotensin-converting enzyme 2 (ACE2)
32354022 2020. ACE2: The key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel?
32306452 2020. Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword?
32451080 ä. A possible strategy to fight COVID-19: Interfering with spike glycoprotein trimerization
